[ad_1]
TOKYO, March 20, 2019 / PRNewswire / – G20 Leaders Meet Today at Second Annual Alzheimer's Scientific Roundtable to Invite Japanese Prime Minister Shinzo Abe to act decisively and make the global crisis of Alzheimer's disease one of the main goals of this year's G20 summit program. The global consortium of researchers, academics, government officials and private sector leaders met at University of Tokyo by Eisai Co., Ltd., ResearchersAgainstAlzheimer (a network of UsAgainstAlzheimer's), the Global CEO Initiative on Alzheimer's Disease, the University of Tokyoand the Health and Global Policy Institute.
"Alzheimer's disease and related dementias are the global public health crises of 21st century. There are 50 million people in the world who are suffering from this disease, and that number will reach 82 million by 2030 unless we act now, "he said. George Vradenburg, President of UsAgainstAlzheimer and organizer of the Global CEO Initiative on Alzheimer's Disease. "The good news is that we know a lot more about Alzheimer's disease than it was a year ago – and that we are optimistic for the future. need to redouble our efforts to fight this disease, "said Vradenburg.
"It is currently estimated that 5 million people die each year from Alzheimer's and dementia-related causes, and the majority of these deaths occur in non-G7 G20 countries." Emergency and a global collaboration is shouting.The time has come for the G20 to embrace the goal of ending the disease by 2025, "concluded Vradenburg.
"The latest scientific data demonstrate that Alzheimer's disease is no longer considered a fatality of old age.In his lifetime, the overall health of a person will have a marked impact on health." Preventive measures taken at each stage of life will benefit brain health later in life, delay cognitive decline, and minimize the risk of developing Alzheimer's disease. " Takeshi Iwatsubo, Professor of Neuropathology at the University of Tokyo. "It is more important than ever to broaden the global discussion of Alzheimer's disease to include brain health." Prime Minister Abe, as the G20's global host this year, is perfectly placed to achieve it. "
Organizers of the roundtable also stressed the need for a global infrastructure to link clinical trial sites. "Working in silos will not bring us closer to treating this disease by 2025. We need an international network of clinical trial sites that can build partnerships and create global networks." support for clinical research ", said Kiyoshi Kurokawa, President of the Health and Global Policy Institute. "At a time when researchers are beginning to understand the underlying pathophysiology of the disease, interdisciplinary collaboration is more crucial than ever, but Prime Minister Abe must recognize that he has the opportunity to lead this issue at the global level – not just the G20 in 2019, but for the years to come ".
The drug development pipeline for Alzheimer's is robust, with more than 100 promising therapies in development. However, more investment and innovation is needed to advance drugs in clinical trials, particularly from phase 2 to phase 3, and to bring new drugs to the market faster. Conference participants agreed that to accelerate drug development efforts, we must also work simultaneously on the development of Alzheimer's biomarkers, which will improve detection rates and improve the quality of life. fast and accurate diagnostics at a global scale and accelerate the adoption of innovative treatments.
"I have no doubt that we will find a cure for Alzheimer's disease, but the development of pharmacological treatments has been more complex than expected," he said. Ivan Cheung, Chairman of the Neurology Business Group at Eisai Co., Ltd. "Biomarkers are an important way to stimulate drug development and increase participation in clinical trials." At this year's G20 summit, Prime Minister Abe should highlight the importance of biomarkers and trials the design will play in future clinical trials. "
Addressing the global crisis of Alzheimer's disease during the G20 is a crucial step to strengthen the increasingly coordinated global efforts to combat Alzheimer's disease over the last ten years years.
"We look forward to continuing our work with the G20 and G7 Health Ministers, the US Government and the Japanese authorities as we strive to find solutions to this global public health crisis," added Vradenburg. "UsAgainstAlzheimer & # 39; s and its partners collectively represent tens of millions of people affected by this horrible disease." We will continue to insist that world leaders prioritize Alzheimer's disease and the brain when this year's G20 summit. Osaka and beyond."
Contact Melissa Green202.429.4940 | [email protected]
SOURCE UsAgainstAlzheimer & # 39; s
Source link
